The first production of generic medicine "nedanib soft capsule"

According to the official wechat of Sinopharm group, the first generic drug of "nedanib soft capsule" of enpip Pharmaceutical Co., Ltd of Sinopharm group has been put into production recently The drug was originally developed as nitedanib eylate (ofev ®) of Boehringer Ingelheim, with a sales volume of 1.1 billion euros in 2018, up 28.7% year on year Sinopharm group nedanib has applied for the new four generic drugs and is already in the first echelon of R & D, and is deemed to have passed the consistency evaluation after being approved Nidanib is a triple kinase inhibitor, which targets platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) The data collected from three key studies showed that ofev could delay the progression of IPF by about 50%, significantly reduce the risk of acute exacerbation of IPF by 47%, reduce the risk of all-cause mortality by 30%, and significantly reduce the mortality during treatment by 43% According to the inquiry of the Chinese patent office, the compound patent (Publication No.: cn1671660a) of the original research on nedanib ethanesulfonate will expire on July 18, 2023, and the group will take the lead in layout, and can be put on the Chinese market as soon as the patent expires.